Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Signs and Symptoms Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

NCT04645953
View directory record Official record
Conditions
Cyclic Vomiting Syndrome
Interventions
3mg AZ-010, 1mg AZ010, Staccato Placebo
Combination Product
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Lancaster, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 15, 2026, 1:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

NCT01504477
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Panitumumab and bortezomib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

NCT00546715
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Dose and Nonalcoholic Fatty Liver Disease

NCT00771108
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
exercise
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 15, 2026, 1:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

NCT04017650
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Progressive Disease, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 15, 2026, 1:51 PM EDT
Terminated Phase 2 Interventional Results available

Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)

NCT02417974
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fecal Microbiota Transplant (FMT)
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

NCT03877718
View directory record Official record
Conditions
Migraine, Pain, Nausea, Vomiting, Aura
Interventions
Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo
Drug · Other
Lead sponsor
Charleston Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrative Cognitive-Affective Therapy for Binge Eating Disorder

NCT02043496
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Integrative Cognitive-Affective Therapy, CBT-Guided Self Help
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2020 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Computer Aided Detection of Polyps During Colonoscopy Procedures

NCT04195646
View directory record Official record
Conditions
Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyps
Interventions
EndoVigilant CAD Software
Device
Lead sponsor
EndoVigilant Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Palo Alto, California • Greenbelt, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional Results available

Aprepitant for Post-operative Nausea

NCT01020903
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Aprepitant, Placebo
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Aromatherapy Decrease Postoperative Nausea and Vomiting?

NCT03577496
View directory record Official record
Conditions
Nausea, Postoperative
Interventions
Peppermint oil
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 15, 2026, 1:51 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comprehensive Outcomes for After Cancer Health

NCT05349227
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Interventions
Digital Health Coaching Program, Fitbit
Behavioral · Device
Lead sponsor
Pack Health
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Early Phase 1 Interventional Results available

NAC +taVNS in IDM Who Are Poor Oral Feeders

NCT04632069
View directory record Official record
Conditions
Infant of Diabetic Mother, Oxidative Stress, Vagus Nerve Stimulation, Feeding Disorders
Interventions
N acetyl cysteine + vagus nerve stimulation
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
3 Weeks to 5 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

NCT00471094
View directory record Official record
Conditions
Esophagitis
Interventions
Ilaprazole, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
94
States / cities
Hueytown, Alabama • Huntsville, Alabama • Chandler, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 15, 2026, 1:51 PM EDT
Terminated Phase 2 Interventional Results available

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

NCT04066894
View directory record Official record
Conditions
Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions
Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery
Procedure · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

NCT07215351
View directory record Official record
Conditions
Constipation, Bloating
Interventions
Dietary supplement for digestive health, placebo capsule
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Phase 4 Interventional Results available

An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease

NCT00701129
View directory record Official record
Conditions
Pompe Disease, Glycogen Storage Disease Type II
Interventions
Alglucosidase Alfa, Methotrexate, Rituximab
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Phase 2 Interventional

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

NCT00676832
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, COLAL-PRED
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2010 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Not applicable Interventional

The Liver Health Study for Patients with NAFLD

NCT03151798
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions
Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies
Behavioral · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Years to 65 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 15, 2026, 1:51 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
56
States / cities
Fort Smith, Arkansas • Hawthorne, California • La Mesa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 1:51 PM EDT
Recruiting No phase listed Observational

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

NCT06660342
View directory record Official record
Conditions
Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
Interventions
Vonoprazan
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 1:51 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation

NCT02137642
View directory record Official record
Conditions
Chronic Constipation
Interventions
RM-131, Placebo
Drug
Lead sponsor
Motus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 15, 2026, 1:51 PM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 15, 2026, 1:51 PM EDT
Recruiting Not applicable Interventional

Innovations in Personalizing Treatment Study

NCT06208605
View directory record Official record
Conditions
Eating Disorders
Interventions
Transdiagnostic Network Informed Personalized Treatment, Enhanced Cognitive Behavioral Therapy for Eating Disorders
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 15, 2026, 1:51 PM EDT